Key result
Levosimendan for peripartum cardiomyopathy linked to more complications and blood transfusions versus no treatment.
Why the study?
While levosimendan is considered beneficial in heart failure and cardiogenic shock, evidence supporting its use in peripartum cardiomyopathy is limited.
Does levosimendan treatment improve outcomes or increase complications in women hospitalized with peripartum cardiomyopathy?
Does levosimendan treatment improve outcomes or increase complications in women hospitalized with peripartum cardiomyopathy?
In a national German cohort of women with peripartum cardiomyopathy, levosimendan use was associated with significantly higher rates of complications, bleeding, and mechanical circulatory support, likely reflecting its use as a rescue therapy in more critically ill patients.
Answers are grounded in this paper and cite their sources.
Caution advised with levosimendan in peripartum cardiomyopathy; challenges benefits seen in prior HF and cardiogenic shock studies.
Background: Peripartum cardiomyopathy (PPCM) is a rare form of heart failure occurring during the last month of pregnancy or within five months postpartum. While levosimendan is considered beneficial in heart failure and cardiogenic shock, evidence supporting its use in PPCM is limited. This study investigated the prevalence of PPCM in Germany and evaluated outcomes associated with levosimendan use. Methods: Using national data from the German Statistical Office, all pregnant women diagnosed with PPCM and hospitalized between 2009 and 2022 were included. Patients were categorized into groups based on levosimendan treatment. Demographics, treatment modalities, peripartum complications, and transfusion rates were analyzed. Results: The prevalence of PPCM in Germany is 0.01%; 3.60% of patients received levosimendan, mostly after childbirth (61.76%). Peripartum complications and the use of mechanical circulatory support devices were significantly higher in the levosimendan group (p < 0.0001). Women in the levosimendan group suffered significantly more often from intrapartum bleeding and increased rates of blood transfusion compared to women in the non-levosimendan group. Conclusions: PPCM is a rare disease in Germany with a prevalence of 0.01%. Despite higher complication rates in women with levosimendan treatment, further studies are necessary to help determine the role and timing of levosimendan in the treatment of women with PPCM.
No takes yet. Share an insight, caveat, or question.
Kloka et al. (2026) studied this question. Women treated with levosimendan for peripartum cardiomyopathy experienced significantly higher rates of peripartum complications and blood transfusions compared to those untreated.
Synapse has enriched 10 related papers. Consider them for comparative context: